Cargando…
Metformin promotes susceptibility to experimental Leishmania braziliensis infection
BACKGROUND: Metformin (MET) is a hypoglycemic drug used for the treatment of diabetes, despite interference in host immunity against microorganisms. Cutaneous infection caused by pathogens such as Leishmania braziliensis (Lb), the agent responsible for cutaneous leishmaniasis (CL) in Brazil, represe...
Autores principales: | Lima, Filipe Rocha, Ferreira, Lais de Melo, Malta, Tainá Alves, Bonyek-Silva, Icaro, Santos, Reinan Lima, Tavares, Natália Machado, de Carvalho Filho, Edgar Marcelino, Arruda, Sérgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Oswaldo Cruz, Ministério da Saúde
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668079/ https://www.ncbi.nlm.nih.gov/pubmed/33206822 http://dx.doi.org/10.1590/0074-02760200272 |
Ejemplares similares
-
Molecular Aspects of Dendritic Cell Activation in Leishmaniasis: An Immunobiological View
por: Tibúrcio, Rafael, et al.
Publicado: (2019) -
Unbalanced production of LTB(4)/PGE(2) driven by diabetes increases susceptibility to cutaneous leishmaniasis
por: Bonyek-Silva, Icaro, et al.
Publicado: (2020) -
Dogs as Reservoirs for Leishmania braziliensis
por: Dantas-Torres, Filipe
Publicado: (2011) -
Integrated Analysis Reveals That miR-193b, miR-671, and TREM-1 Correlate With a Good Response to Treatment of Human Localized Cutaneous Leishmaniasis Caused by Leishmania braziliensis
por: Nunes, Sara, et al.
Publicado: (2018) -
A New Target Organ of Leishmania (Viannia) braziliensis Chronic Infection: The Intestine
por: dos Santos, Amanda Gubert Alves, et al.
Publicado: (2021)